DOV KADMON to Prostate-Specific Antigen
This is a "connection" page, showing publications DOV KADMON has written about Prostate-Specific Antigen.
Connection Strength
1.051
-
The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005 Jun; 173(6):1923-5.
Score: 0.215
-
Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res. 2000 Oct; 6(10):3845-9.
Score: 0.156
-
Beyond prostate specific antigen--markers for prostate cancer for the 21st Century. J Urol. 2000 Mar; 163(3):828.
Score: 0.150
-
Pitfalls in interpreting prostate specific antigen velocity. J Urol. 1996 May; 155(5):1655-7.
Score: 0.115
-
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
Score: 0.068
-
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
Score: 0.058
-
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
Score: 0.057
-
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004 Sep; 172(3):900-4.
Score: 0.051
-
Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004 May; 63(5):905-10; discussion 910-1.
Score: 0.050
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.050
-
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
Score: 0.042
-
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998 Aug; 52(2):195-201; discussion 201-2.
Score: 0.034
-
Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995 Mar; 45(3):491-7.
Score: 0.007